Corticosteroids in sepsis: Pathophysiological rationale and the selection of patients

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 10, Issue 3, 2010, Pages 266-273

  Salluh, Jorge Ibrain Figueira ^a   Bozza, Fernando Augusto ^b   Japiassú, André Miguel ^b   Neto, Hugo Caire Castro Faria ^c   Bozza, Patricia Torres ^c   Póvoa, Pedro ^d  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

Author keywords

Bacterial infections; Glucocorticoids; Sepsis; Septic shock; Therapeutics

Indexed keywords

11 HYDROXYCORTICOSTEROID; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; C REACTIVE PROTEIN; CYCLOOXYGENASE 2; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 6; PROSTACYCLIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ADRENAL DISEASE; ARTICLE; BACTERIAL MENINGITIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; DRUG EFFICACY; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOXEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATIENT SELECTION; PNEUMOCYSTIS PNEUMONIA; PROTEIN EXPRESSION; RESPIRATORY FAILURE; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TREATMENT RESPONSE;

EID: 78549295537     PISSN: 18715303     EISSN: None     Source Type: Journal    
DOI: 10.2174/187153010791936865     Document Type: Article

References (111)

1. Perla, D. and Marmorston, J. (1940) Suprarenal cortical hormone and salt in the treatment of pneumonia and other severe infections. Endocrinology, 27, 367-374.
2. Schumer, W. (1976) Steroids in the treatment of clinical septic shock. Ann. Surg., 184, 333-341.
3. Bone, R.C.; Fisher, C.J. Jr.; Clemmer, T.P.; Slotman, G.J.; Metz, C.A. and Balk, R.A. (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med., 317, 653-658.
4. Bernard, G.R.; Luce, J.M.; Sprung, C.L.; Rinaldo, J.E.; Tate, R.M.; Sibbald, W.J.; Kariman, K.; Higgins, S.; Bradley, R. and Metz, C.A. (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. N. Engl. J. Med., 317, 1565-1570.
5. Rothwell, P.M.; Udwadia, Z.F. and Lawler, P.G. (1991) Cortisol response to corticotropin and survival in septic shock. Lancet, 337, 582-583.
6. Annane, D.; Sebille, V.; Troche, G.; Raphael, J.C.; Gajdos, P. and Bellissant, E. (2000) A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotro-pin. JAMA, 283, 1038-1045.
7. Annane, D.; Sebille, V.; Charpentier, C.; Bollaert, P.E.; Francois, B.; Korach, J.M.; Capellier, G.; Cohen, Y.; Azoulay, E.; Troche, G.; Chaumet-Riffaud, P. and Bellissant, E. (2002) Effect of treat-ment with low doses of hydrocortisone and fludrocortisone on mor-tality in patients with septic shock. JAMA, 288, 862-871.
8. Bollaert, P.E.; Charpentier, C.; Levy, B.; Debouverie, M.; Audibert, G. and Larcan, A. (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med., 26, 645-650.
9. Briegel, J.; Forst, H.; Haller, M.; Schelling, G.; Kilger, E.; Kuprat, G.; Hemmer, B.; Hummel, T.; Lenhart, A.; Heyduck, M.; Stoll, C. and Peter, K. (1999) Stress doses of hydrocortisone reverse hy-perdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit. Care Med., 27, 723-732.
10. Oppert, M.; Reinicke, A.; Graf, K.J.; Barckow, D.; Frei, U. and Eckardt, K.U. (2000) Plasma cortisol levels before and during low-dose hydrocortisone therapy and their relationship to hemo-dynamic improvement in patients with septic shock. Intensive Care Med., 26, 1747-1755.
11. Keh, D.; Boehnke, T.; Weber-Cartens, S.; Schulz, C.; Ahlers, O.; Bercker, S.; Volk, H.D.; Doecke, W.D.; Falke, K.J. and Gerlach, H. (2003) Immunologic and hemodynamic effects of low-dose hy-drocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am. J. Respir. Crit. Care Med., 167, 512-520.
12. Dellinger, R.P.; Carlet, J.M.; Masur, H.; Gerlach, H.; Calandra, T.; Cohen, J.; Gea-Banacloche, J.; Keh, D.; Marshall, J.C.; Parker, M.M.; Ramsay, G.; Zimmerman, J.L.; Vincent, J.L. and Levy, M.M. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med., 32, 858-873.
13. Salluh, J.I.; Bozza, P.T. and Bozza, F.A. (2008) Surviving sepsis campaign: a critical reappraisal. Shock, 30, 70-72.
14. Singer, M. (2006) The Surviving Sepsis guidelines: evidence-based ... or evidence-biased? Crit. Care Resusc., 8, 244-245.
15. Sprung, C.L.; Annane, D.; Keh, D.; Moreno, R.; Singer, M.; Freivogel, K.; Weiss, Y.G.; Benbenishty, J.; Kalenka, A.; Forst, H.; Laterre, P.F.; Reinhart, K.; Cuthbertson, B.H.; Payen, D. and Briegel, J. (2008) Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med., 358, 111-124.
16. Salluh, J.I. and Soares, M. (2008) New recommendations for the use of corticosteroids in sepsis: not so fast! Crit. Care Med., 36, 2489-2490.
17. Vincent, J.L. (2008) Steroids in sepsis: another swing of the pendulum in our clinical trials. Crit. Care, 12, 141.
18. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L. and Vincent, J.L. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med., 36, 296-327.
19. Japiassu, A.M.; Salluh, J.I.; Bozza, P.T.; Bozza, F.A. and Castro-Faria-Neto, H.C. (2009) Revisiting steroid treatment for septic shock: molecular actions and clinical effects--a review. Mem. Inst. Oswaldo Cruz, 104, 531-548.
20. Chrousos, G.P. (1995) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med., 332, 1351-1362.
21. Williams, M. and Menon, D.K. (2009); In 2009 Yearbook of Intensive Care and Emergency Medicine, (J. L. Vincent, Ed.); Springer: Berlin, pp. 741-752.
22. Orth, D.N.; Kovacs, W.J. and DeBold, C.R. (1992); In Textbook of Endocrinology, (J. D. Wilson; D. W. Foster, Eds.); W. S. Saunders Company: Philadelphia, pp. 489-531.
23. Hammond, G.L.; Smith, C.L.; Underhill, C.M. and Nguyen, V.T. (1990) Interaction between corticosteroid binding globulin and activated leukocytes in vitro. Biochem. Biophys. Res. Commun., 172, 172-177.
24. Vogeser, M. and Briegel, J. (2007) Effect of temperature on protein binding of cortisol. Clin. Biochem., 40, 724-727.
25. Ho, J.T.; Al-Musalhi, H.; Chapman, M.J.; Quach, T.; Thomas, P.D.; Bagley, C.J.; Lewis, J.G. and Torpy, D.J. (2006) Septic shock and sepsis: a comparison of total and free plasma cortisol levels. J. Clin. Endocrinol. Metab., 91, 105-114.
26. Marik, P.E. (2009) Critical illness-related corticosteroid insufficiency. Chest, 135, 181-193.
27. Prigent, H.; Maxime, V. and Annane, D. (2004) Clinical review: corticotherapy in sepsis. Crit. Care, 8, 122-129.
28. Cai, T.Q.; Wong, B.; Mundt, S.S.; Thieringer, R.; Wright, S.D. and Hermanowski-Vosatka, A. (2001) Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not -2 in human aortic smooth muscle cells by inflammatory stimuli. J. Steroid Biochem. Mol. Biol., 77, 117-122.
29. Kino, T.; De Martino, M.U.; Charmandari, E.; Mirani, M. and Chrousos, G.P. (2003) Tissue glucocorticoid resistance/hypersensitivity syndromes. J. Steroid Biochem. Mol. Biol., 85, 457-467.
30. Galon, J.; Franchimont, D.; Hiroi, N.; Frey, G.; Boettner, A.; Ehrhart-Bornstein, M.; O'Shea, J.J.; Chrousos, G.P. and Bornstein, S.R. (2002) Gene profiling reveals unknown enhancing and sup-pressive actions of glucocorticoids on immune cells. FASEB J., 16, 61-71.
31. Scheinman, R.I.; Gualberto, A.; Jewell, C.M.; Cidlowski, J.A. and Baldwin, A.S. Jr. (1995) Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol. Cell. Biol., 15, 943-953.
32. Chinenov, Y. and Rogatsky, I. (2007) Glucocorticoids and the innate immune system: crosstalk with the toll-like receptor signaling network. Mol. Cell. Endocrinol., 275, 30-42.
33. Meduri, G.U. (1999) New rationale for glucocorticoid treatment in septic shock. J. Chemother., 11, 541-550.
34. Leung, D.Y.; Hamid, Q.; Vottero, A.; Szefler, S.J.; Surs, W.; Minshall, E.; Chrousos, G.P. and Klemm, D.J. (1997) Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J. Exp. Med., 186, 1567-1574.
35. Orlikowsky, D.; Castel, M. and Annane, D. (2003) Acute effect of a single intravenous bolus of 50 mg hydrocortisone on cardiovascular autonomic modulation in septic shock [abstract]. Crit. Care Med., 31, A124.
36. Annane, D.; Bellissant, E.; Sebille, V.; Lesieur, O.; Mathieu, B.; Raphael, J.C. and Gajdos, P. (1998) Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br. J. Clin. Pharmacol., 46, 589-597.
37. Hafezi-Moghadam, A.; Simoncini, T.; Yang, Z.; Limbourg, F.P.; Plumier, J.C.; Rebsamen, M.C.; Hsieh, C.M.; Chui, D.S.; Thomas, K.L.; Prorock, A.J.; Laubach, V.E.; Moskowitz, M.A.; French, B.A.; Ley, K. and Liao, J.K. (2002) Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat. Med., 8, 473-479.
38. Marik, P.E.; Pastores, S.M.; Annane, D.; Meduri, G.U.; Sprung, C.L.; Arlt, W.; Keh, D.; Briegel, J.; Beishuizen, A.; Dimopoulou, I.; Tsagarakis, S.; Singer, M.; Chrousos, G.P.; Zaloga, G.; Bokhari, F. and Vogeser, M. (2008) Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit. Care Med., 36, 1937-1949.
39. Annane, D.; Bellissant, E.; Bollaert, P.E.; Briegel, J.; Confalonieri, M.; de Gaudio, R.; Keh, D.; Kupfer, Y.; Oppert, M. and Meduri, G.U. (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA, 301, 2362-2375.
40. Cole, T.J.; Blendy, J.A.; Monaghan, A.P.; Krieglstein, K.; Schmid, W.; Aguzzi, A.; Fantuzzi, G.; Hummler, E.; Unsicker, K. and Schutz, G. (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev., 9, 1608-1621.
41. Bertini, R.; Bianchi, M. and Ghezzi, P. (1988) Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J. Exp. Med., 167, 1708-1712.
42. Reichardt, H.M.; Umland, T.; Bauer, A.; Kretz, O. and Schutz, G. (2000) Mice with an increased glucocorticoid receptor gene dosage show enhanced resistance to stress and endotoxic shock. Mol. Cell. Biol., 20, 9009-9017.
43. Hawes, A.S.; Rock, C.S.; Keogh, C.V.; Lowry, S.F. and Calvano, S.E. (1992) In vivo effects of the antiglucocorticoid RU 486 on glucocorticoid and cytokine responses to Escherichia coli endotoxin. Infect. Immun., 60, 2641-2647.
44. Miech, R.P. (2005) Pathophysiology of mifepristone-induced septic shock due to Clostridium sordellii. Ann. Pharmacother., 39, 1483-1488.
45. Lamberts, S.W.; Bruining, H.A. and de Jong, F.H. (1997) Corticos-teroid therapy in severe illness. N. Engl. J. Med., 337, 1285-1292.
46. Bone, R.C. (1991) The pathogenesis of sepsis. Ann. Intern. Med., 115, 457-469.
47. Cronin, L.; Cook, D.J.; Carlet, J.; Heyland, D.K.; King, D.; Lansang, M.A. and Fisher, C.J. Jr. (1995) Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med., 23, 1430-1439.
48. Duma, D.; Silva-Santos, J.E. and Assreuy, J. (2004) Inhibition of glucocorticoid receptor binding by nitric oxide in endotoxemic rats. Crit. Care Med., 32, 2304-2310.
49. [49] Briel, M.; Bucher, H.C.; Boscacci, R. and Furrer, H. (2006) Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst. Rev., 3, CD006150.
50. van de Beek, D.; de Gans, J.; McIntyre, P. and Prasad, K. (2007) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst. Rev., 1, CD004405.
51. Soni, A.; Pepper, G.M.; Wyrwinski, P.M.; Ramirez, N.E.; Simon, R.; Pina, T.; Gruenspan, H. and Vaca, C.E. (1995) Adrenal insufficiency occurring during septic shock: incidence, outcome, and relationship to peripheral cytokine levels. Am. J. Med., 98, 266-271.
52. Briegel, J.; Jochum, M.; Gippner-Steppert, C. and Thiel, M. (2001) Immunomodulation in septic shock: hydrocortisone differentially regulates cytokine responses. J. Am. Soc. Nephrol., 12, S70-S74.
53. Briegel, J.; Kellermann, W.; Forst, H.; Haller, M.; Bittl, M.; Hoffmann, G.E.; Buchler, M.; Uhl, W. and Peter, K. (1994) Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin. Investig., 72, 782-787.
54. Agusti, C.; Rano, A.; Filella, X.; Gonzalez, J.; Moreno, A.; Xaubet, A. and Torres, A. (2003) Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest, 123, 488-498.
55. Hambach, L.; Eder, M.; Dammann, E.; Schrauder, A.; Sykora, K.W.; Dieterich, C.; Kirschner, P.; Novotny, J.; Ganser, A. and Hertenstein, B. (2002) Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. Haematologica, 87, 643-651.
56. Schuttrumpf, S.; Binder, L.; Hagemann, T.; Berkovic, D.; Trumper, L. and Binder, C. (2006) Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin. Infect. Dis., 43, 468-473.
57. Stolz, D.; Stulz, A.; Muller, B.; Gratwohl, A. and Tamm, M. (2007) BAL neutrophils, serum procalcitonin, and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest, 132, 504-514.
58. Salluh, J.I.; Povoa, P.; Soares, M.; Castro-Faria-Neto, H.C.; Bozza, F.A. and Bozza, P.T. (2008) The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit. Care, 12, R76.
59. Monton, C.; Ewig, S.; Torres, A.; El-Ebiary, M.; Filella, X.; Rano, A. and Xaubet, A. (1999) Role of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur. Respir. J., 14, 218-220.
60. Marik, P.; Kraus, P.; Sribante, J.; Havlik, I.; Lipman, J. and Johnson, D.W. (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest, 104, 389-392.
61. Confalonieri, M.; Urbino, R.; Potena, A.; Piattella, M.; Parigi, P.; Puccio, G.; Della Porta, R.; Giorgio, C.; Blasi, F.; Umberger, R. and Meduri, G.U. (2005) Hydrocortisone infusion for severe com- munity-acquired pneumonia: a preliminary randomized study. Am. J. Respir. Crit. Care Med., 171, 242-248.
62. Mikami, K.; Suzuki, M.; Kitagawa, H.; Kawakami, M.; Hirota, N.; Yamaguchi, H.; Narumoto, O.; Kichikawa, Y.; Kawai, M.; Tashimo, H.; Arai, H.; Horiuchi, T. and Sakamoto, Y. (2007) Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung, 185, 249-255.
63. Salluh, J.I.; Soares, M.; Coelho, L.; Bozza, F.A.; Verdeal, J.; Castro-Faria-Neto, H. C.; Lapa e Silva, J.; Bozza, P.T. and Povoa, P. (2009) Impact of systemic corticosteroids on the outcome of patients with severe community-acquired pneumonia: a cohort study [abstract]. Am. J. Respir. Crit. Care Med., 178, A1716.
64. Snijders, C.S.; de Graaff, T.S. and van der Werf, W.G. (2009) Clinical efficacy of prednisolone in patients with community- acquired pneumonia, a randomized clinical trial [abstract]. Am. J. Respir. Crit. Care Med., 178, A6116.
65. Vigushin, D.M.; Pepys, M.B. and Hawkins, P.N. (1993) Metabolic and scintigraphic studies of radioiodinated human C-reactive pro- tein in health and disease. J. Clin. Invest., 91, 1351-1357.
66. Povoa, P. (2002) C-reactive protein: a valuable marker of sepsis. Intensive Care Med., 28, 235-243.
67. Heinrich, P.C.; Castell, J.V. and Andus, T. (1990) Interleukin-6 and the acute phase response. Biochem. J., 265, 621-636.
68. Gruys, E.; Toussaint, M.J.; Niewold, T.A. and Koopmans, S.J. (2005) Acute phase reaction and acute phase proteins. J. Zhejiang Univ. Sci. B, 6, 1045-1056.
69. Etienne, A.; Hecquet, F.; Soulard, C.; Touvay, C.; Clostre, F. and Braquet, P. (1986) The relative role of PAF-acether and icosanoids in septic shock. Pharmacol. Res. Commun., 18, 71-79.
70. Halushka, P.V.; Reines, H.D.; Barrow, S.E.; Blair, I.A.; Dollery, C.T.; Rambo, W.; Cook, J.A. and Wise, W.C. (1985) Elevated plasma 6-keto-prostaglandin F1 alpha in patients in septic shock. Crit. Care Med., 13, 451-453.
71. Smedegard, G.; Cui, L.X. and Hugli, T.E. (1989) Endotoxin-induced shock in the rat. A role for C5a. Am. J. Pathol., 135, 489- 497.
72. Thiemermann, C. and Vane, J. (1990) Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipo- polysaccharides in the rat in vivo. Eur. J. Pharmacol., 182, 591-595.
73. Kosaka, H.; Watanabe, M.; Yoshihara, H.; Harada, N. and Shiga, T. (1992) Detection of nitric oxide production in lipopolysaccha- ride-treated rats by ESR using carbon monoxide hemoglobin. Bio- chem. Biophys. Res. Commun., 184, 1119-1124.
74. Standen, N.B.; Quayle, J.M.; Davies, N.W.; Brayden, J.E.; Huang, Y. and Nelson, M.T. (1989) Hyperpolarizing vasodilators activate ATP-sensitive K+ channels in arterial smooth muscle. Science, 245, 177-180.
75. Landry, D.W. and Oliver, J.A. (1992) The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J. Clin. Invest., 89, 2071-2074.
76. Sorrentino, R.; d'Emmanuele di Villa Bianca, R.; Lippolis, L.; Sorrentino, L.; Autore, G. and Pinto, A. (1999) Involvement of ATP-sensitive potassium channels in a model of a delayed vascular hyporeactivity induced by lipopolysaccharide in rats. Br. J. Phar- macol., 127, 1447-1453.
77. +-channels in vascular hyporeactivity induced by endotoxin. Naunyn Schmiedebergs Arch. Pharmacol., 359, 493-499.
78. Terluk, M.R.; da Silva-Santos, J.E. and Assreuy, J. (2000) In- volvement of soluble guanylate cyclase and calcium-activated po- tassium channels in the long-lasting hyporesponsiveness to phen- ylephrine induced by nitric oxide in rat aorta. Naunyn Schmiede- bergs Arch. Pharmacol., 361, 477-483.
79. Brem, A.S.; Bina, R.B.; Mehta, S. and Marshall, J. (1999) Gluco- corticoids inhibit the expression of calcium-dependent potassium channels in vascular smooth muscle. Mol. Genet. Metab., 67, 53-57.
80. d'Emmanuele di Villa Bianca, R.; Lippolis, L.; Autore, G.; Popolo, A.; Marzocco, S.; Sorrentino, L.; Pinto, A. and Sorrentino, R. (2003) Dexamethasone improves vascular hyporeactivity induced by LPS in vivo by modulating ATP-sensitive potassium channels activity. Br. J. Pharmacol., 140, 91-96.
81. Li, H. and Forstermann, U. (2000) Nitric oxide in the pathogenesis of vascular disease. J. Pathol., 190, 244-254.
82. Galigniana, M.D.; Piwien-Pilipuk, G. and Assreuy, J. (1999) Inhibition of glucocorticoid receptor binding by nitric oxide. Mol. Pharmacol., 55, 317-323.
83. Annane, D. and Bellissant, E. (2000) Prognostic value of cortisol response in septic shock. JAMA, 284, 308-309.
84. Sprung, C.L.; Caralis, P.V.; Marcial, E.H.; Pierce, M.; Gelbard, M.A.; Long, W.M.; Duncan, R.C.; Tendler, M.D. and Karpf, M. (1984) The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N. Engl. J. Med., 311, 1137-1143.
85. Chawla, K.; Kupfer, Y. and Tessler, S. (2000) Prognostic value of cortisol response in septic shock. JAMA, 284, 309.
86. Oppert, M.; Schindler, R.; Husung, C.; Offermann, K.; Graf, K.J.; Boenisch, O.; Barckow, D.; Frei, U. and Eckardt, K.U. (2005) Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit. Care Med., 33, 2457-2464.
87. Bellissant, E. and Annane, D. (2000) Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock. Clin. Pharmacol. Ther., 68, 293-303.
88. Annane, D.; Maxime, V.; Ibrahim, F.; Alvarez, J.C.; Abe, E. and Boudou, P. (2006) Diagnosis of adrenal insufficiency in severe sepsis and septic shock. Am. J. Respir. Crit. Care Med., 174, 1319-1326.
89. Salluh, J.I.; Verdeal, J.C.; Mello, G.W.; Araujo, L.V.; Martins, G.A.; de Sousa Santino, M. and Soares, M. (2006) Cortisol levels in patients with severe community-acquired pneumonia. Intensive Care Med., 32, 595-598.
90. Salgado, D.R.; Verdeal, J.C. and Rocco, J.R. (2006) Adrenal function testing in patients with septic shock. Crit. Care, 10, R149.
91. Marik, P. and Zaloga, G. (2000) Prognostic value of cortisol response in septic shock. JAMA, 284, 308-309.
92. de Jong, M.F.; Beishuizen, A.; Spijkstra, J.J. and Groeneveld, A.B. (2007) Relative adrenal insufficiency as a predictor of disease severity, mortality, and beneficial effects of corticosteroid treatment in septic shock. Crit. Care Med., 35, 1896-1903.
93. Salgado, D.R.; Rocco, J.R. and Rosso Verdeal, J.C. (2008) Adrenal function in different subgroups of septic shock patients. Acta Anaesthesiol. Scand., 52, 36-44.
94. Pariante, C.M.; Pearce, B.D.; Pisell, T.L.; Sanchez, C.I.; Po, C.; Su, C. and Miller, A.H. (1999) The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology, 140, 4359-4366.
95. Guzman, J.A. and Guzman, C.B. (2007) Adrenal exhaustion in septic patients with vasopressor dependency. J. Crit. Care, 22, 319-323.
96. Hamrahian, A.H.; Oseni, T.S. and Arafah, B.M. (2004) Measurements of serum free cortisol in critically ill patients. N. Engl. J. Med., 350, 1629-1638.
97. Christ-Crain, M.; Stolz, D.; Jutla, S.; Couppis, O.; Muller, C.; Bingisser, R.; Schuetz, P.; Tamm, M.; Edwards, R.; Muller, B. and Grossman, A.B. (2007) Free and total cortisol levels as predictors of severity and outcome in community-acquired pneumonia. Am. J. Respir. Crit. Care Med., 176, 913-920.
98. Salluh, J.I.; Bozza, F.A.; Soares, M.; Verdeal, J.C.; Castro-Faria-Neto, H.C.; Lapa, E.S.J.R. and Bozza, P.T. (2008) Adrenal re-sponse in severe community-acquired pneumonia: impact on out-comes and disease severity. Chest, 134, 947-954.
99. Salluh, J.I. and Bozza, P.T. (2008) Biomarkers of sepsis: lost in translation? Crit. Care Med., 36, 2192-2194.
100. Bozza, F.A.; Bozza, P.T. and Castro Faria Neto, H.C. (2005) Be-yond sepsis pathophysiology with cytokines: what is their value as biomarkers for disease severity? Mem. Inst. Oswaldo Cruz., 100, 217-221.
101. Bozza, F.A.; Salluh, J.I.; Japiassu, A.M.; Soares, M.; Assis, E.F.; Gomes, R.N.; Bozza, M.T.; Castro-Faria-Neto, H.C. and Bozza, P.T. (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit. Care, 11, R49.
102. Marshall, J.C. and Reinhart, K. (2009) Biomarkers of sepsis. Crit. Care Med., 37, 2290-2298.
103. Seely, A.J. and Christou, N.V. (2000) Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit. Care Med., 28, 2193-2200.
104. Meisel, C.; Schefold, J.C.; Pschowski, R.; Baumann, T.; Hetzger, K.; Gregor, J.; Weber-Carstens, S.; Hasper, D.; Keh, D.; Zucker-mann, H.; Reinke, P. and Volk, H. D. (2009) Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med., 180, 640-648.
105. Levy, M.M.; Fink, M.P.; Marshall, J.C.; Abraham, E.; Angus, D.; Cook, D.; Cohen, J.; Opal, S.M.; Vincent, J.L. and Ramsay, G. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med., 31, 1250-1256.
106. Rello, J.; Lisboa, T. and Wunderink, R. (2009) Severe Community-Acquired Pneumonia and PIRO: A New Paradigm of Management. Curr. Infect. Dis. Rep., 11, 343-348.
107. Lisboa, T.; Diaz, E.; Sa-Borges, M.; Socias, A.; Sole-Violan, J.; Rodriguez, A. and Rello, J. (2008) The ventilator-associated pneu-monia PIRO score: a tool for predicting ICU mortality and health-care resources use in ventilator-associated pneumonia. Chest, 134, 1208-1216.
108. Moreno, R.P.; Metnitz, B.; Adler, L.; Hoechtl, A.; Bauer, P. and Metnitz, P.G. (2008) Sepsis mortality prediction based on predisposition, infection and response. Intensive Care Med., 34, 496-504.
109. Bozza, F.A.; Gomes, R.N.; Japiassu, A.M.; Soares, M.; Castro-Faria-Neto, H.C.; Bozza, P.T. and Bozza, M.T. (2004) Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock, 22, 309-313.
110. Emonts, M.; Sweep, F.C.; Grebenchtchikov, N.; Geurts-Moespot, A.; Knaup, M.; Chanson, A.L.; Erard, V.; Renner, P.; Hermans, P.W.; Hazelzet, J.A. and Calandra, T. (2007) Association between high levels of blood macrophage migration inhibitory factor, inap-propriate adrenal response, and early death in patients with severe sepsis. Clin. Infect. Dis., 44, 1321-1328.
111. Sprong, T.; Pickkers, P.; Geurts-Moespot, A.; van der Ven-Jongekrijg, J.; Neeleman, C.; Knaup, M.; Leroy, D.; Calandra, T.; van der Meer, J.W.; Sweep, F. and van Deuren, M. (2007) Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock, 27, 482-487.